Aldoxorubicin - LadRx Corporation
Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - LadRx CorporationLatest Information Update: 06 Jun 2024
Price :
$50 *
At a glance
- Originator KTB Tumorforschungs
- Developer LadRx Corporation
- Class Amines; Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Hexanoic acids; Hydrazines; Maleimides; Naphthacenes; Pyrroles; Small molecules
- Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Soft tissue sarcoma
- Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
- Phase I/II Chondrosarcoma; Colorectal cancer; Osteosarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Most Recent Events
- 03 Jun 2024 LadRx Corporation and XOMA amends the royalty purchase agreement to provide XOMA with a low-single-digit synthetic royalty from future out-license agreements related to aldoxorubicin
- 03 Jun 2024 LadRx Corporation mutually terminates its aldoxorubicin licensing agreement with ImmunityBio and regains rights of aldoxorubicin
- 22 May 2024 NantKwest terminates a phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)